ENDORESIST

  • Novel drug targeting antiestrogen therapy resistance: a paradigm shift in breast cancer treatment
  • ENDORESIST is a translational cancer research project which aims at seizing a major market opportunity by developing SCO-101, a new drug that targets anti-estrogen resistance in breast cancer. We will deliver a clinically validated and safe drug, and a companion diagnostic tool, opening the possibility to find a big pharma buyer/partner to capitalize on the SCO-101 opportunity. ENDORESIST builds around a patient-centric approach, based on biomarker discovery and insights on mechanisms of action.
  • ENDORESIST not yet started and will run for 30 month.
  • Partner to the ENDORESIST project are Scandion Oncology A/S and the Department of Medical Oncology of Erasmus MC, the University Medical Center Rotterdam. 2cureX sees an active exchange between hospital professionals and patients as key in future treatment of cancer patients.

Project Details

Acronym:
ENDORESIST

Duration:
36 months

Start date:
Not started

Topic:
New Treatments for Anti-estrogen Resistance

Funding:
2.2 Mio EUR

Upcoming events

June 2, 2021

Redeye Growth Day 2021, Stockholm

Read more

August 28, 2021

Interim Report Q2 2021

View previous reports

November 25, 2021

Interim Report Q3 2021

View previous reports

February 24, 2022

Year-End Report 2021

View previous reports

IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.